Technology for purifying NK cells and other cell types by concurrent gravity sedimentation and magnetic separation

Patent metadata

Field	Value
Publication number	US-10006840-B2
Application number	US-201214358922-A
Country	US
Kind code	B2
Filing date	Nov 20, 2012
Priority date	Nov 25, 2011
Publication date	Jun 26, 2018
Grant date	Jun 26, 2018

Abstract

The present invention provides methods and compositions for separating cells from a sample containing erythrocytes. The method is for recovering desired cells from a sample containing the desired cells, erythrocytes and undesired cells comprising: a) contacting the sample with a composition, said composition comprising: i) an erythrocytes aggregation reagent ii) at least one antigen recognizing moiety coupled to a magnetic particle, wherein said particle with said at least one antigen recognizing moiety specifically binds to at least one antigen specific for one or more undesired cellular components; b) applying simultaneously i) gravity sedimentation for sedimentation of erythrocytes and ii) a magnetic field gradient to said sample for immobilizing said magnetic particle generating a pellet and a supernatant phase, and c) recovering the desired cells from the supernatant phase. Compositions for the use within the present method are also disclosed.

First claim

The invention claimed is:

1. A depletion method for purifying a target leukocyte subpopulation from a starting sample containing erythrocytes and other types of leukocytes, the method comprising:
combining the starting sample with a cocktail of reagents to form a separation mixture, wherein the cocktail comprises as separate components:
(1) a plurality of different antigen-recognizing moieties specific for cell markers on the other types of leukocytes but not on the target leukocytes, attached directly or indirectly to magnetic particles; and
(2) a preselected choice and concentration of an erythrocyte aggregation reagent;

performing a single separation step of magnetically enforced sedimentation by placing the separation mixture in a magnetic field such that the erythrocytes and the other types of leukocytes form a pellet, leaving a supernatant phase; and
harvesting the target leukocyte subpopulation from the supernatant phase;
wherein the size of the magnetic particles, the concentration of the magnetic particles, the choice of the erythrocyte aggregation reagent, and the concentration of the erythrocyte aggregation reagent in the cocktail of reagents are all preselected such that the single separation step produces a population of the target leukocytes in the supernatant phase from a sample of whole blood that is over 60% pure and constitutes a yield of over 40% of the number of target leukocytes in said sample.

2. The depletion method of claim 1 , wherein the cocktail of reagents further comprises antigen-recognizing moieties that are specific for erythrocytes attached directly or indirectly to magnetic particles.

3. The depletion method of claim 1 , with the proviso that the erythrocyte aggregation agent is not dextran.

4. The depletion method of claim 1 , with the proviso that the cocktail of reagents does not include antigen-recognizing moieties specific for CD235a (glycophorin A).

5. The method of claim 1 , wherein the starting sample is a sample of whole blood.

6. The method of claim 1 , wherein the starting sample is a leukopheresis sample, a buffy coat sample, an umbilical cord sample, or a bone marrow sample.

7. The depletion method of claim 1 , wherein the single separation step produces a population of the target leukocytes in the supernatant phase from the starting sample that is at least 76% pure.

8. The depletion method of claim 1 , wherein the single separation step produces a population of the target leukocytes in the supernatant phase from the starting sample that is at least 90% pure.

9. The depletion method of claim 1 , wherein the single separation step produces a population of the target leukocytes in the supernatant phase that has a yield of at least 66% of the target leukocyte subpopulation in the starting sample.

10. The depletion method of claim 1 , wherein the single separation step produces a population of the target leukocytes in the supernatant phase that has a yield of at least 83% of the target leukocyte subpopulation in the starting sample.

11. The depletion method of claim 1 , wherein the single separation step produces a supernatant phase from which over 99% of the erythrocytes in the sample have been depleted.

12. The method of claim 1 , wherein the pellet is separated into two parts: one part at the bottom of a container in which the mixture is subject to the magnetically enforced sedimentation, the other part along a vertical side of the container.

13. The method of claim 1 , wherein the erythrocytes and the other types of leukocytes from the starting sample form a combined pellet having a curved surface.

14. The method of claim 1 , further comprising removing residual erythrocytes from the cell population recovered from the supernatant phase using an antigen recognizing moiety specific for an erythrocyte specific marker.

15. The method of claim 1 , wherein the target leukocyte subpopulation is a purified population of NK cells, B lymphocytes, T lymphocytes, monocytes, T helper cells, or cytotoxic T cells.

16. The method of claim 15 , wherein the target leukocyte subpopulation is a purified population of NK cells, and the cocktail of reagents contains antigen-recognizing moieties specific for CD3, CD4, CD14, CD15, CD19, CD36, CD61, CD123, CD193, IgE, and T cell receptor (TCR).

17. The method of claim 15 , wherein the target leukocyte subpopulation is a purified population of B lymphocytes, and the cocktail of reagents contains antigen-recognizing moieties specific for CD2, CD14, CD15, CD36, CD43, CD56, CD61, and IgE.

18. The method of claim 15 , wherein the target leukocyte subpopulation is a purified population of T lymphocytes, and the cocktail of reagents contains antigen-recognizing moieties specific for CD11b, CD145, CD15, CD19, CD36, CD56, CD61, CD123, and IgE.

19. The method of claim 15 , wherein the target leukocyte subpopulation is a purified population of monocytes, and the cocktail of reagents contains antigen-recognizing moieties specific for CD3, CD7, CD15, CD19, CD56, CD61, CD123, CD193, CD304, CD335, and IgE.

20. The method of claim 1 , further comprising formulating the leukocytes harvested from the supernatant phase as a pharmaceutical composition by way of a process that includes combining the harvested leukocytes with a pharmaceutical carrier or excipient.

21. A depletion method for purifying a target leukocyte subpopulation from a starting sample containing erythrocytes, thrombocytes, and other types of leukocytes, the method comprising:
combining the starting sample with a cocktail of reagents to form a separation mixture, wherein the cocktail comprises as separate components:
(1) a plurality of different antigen-recognizing moieties specific for cell markers on the other types of leukocytes but not on the target leukocytes, attached directly or indirectly to magnetic particles;
(2) antigen-recognizing moieties specific for platelets, attached directly or indirectly to magnetic particles; and
(3) an erythrocyte aggregation reagent;

performing a single separation step of magnetically enforced sedimentation by placing the separation mixture in a magnetic field such that the erythrocytes, the platelets, and the undesired leukocytes form a pellet, leaving a supernatant phase from which over 90% of the platelets in the starting sample have been depleted; and
harvesting the target leukocytes from the supernatant phase.

22. The depletion method of claim 21 , wherein the antigen-recognizing moieties specific for platelets include moieties specific for CD61, CD62, and/or CD41.

23. The depletion method of claim 21 , wherein the single separation step produces a supernatant phase from which over 97% of the platelets in the sample have been depleted.

24. A depletion method for purifying a target leukocyte subpopulation from a starting sample containing erythrocytes, granulocytes, and other types of leukocytes, the method comprising:
combining the starting sample with a cocktail of reagents to form a separation mixture, wherein the cocktail comprises as separate components:
(1) antigen-recognizing moieties specific for granulocytes, attached directly or indirectly to magnetic particles;
(2) a plurality of different antigen-recognizing moieties specific for cell markers on other types of leukocytes but not on the target leukocytes, attached directly or indirectly to magnetic particles; and
(3) an erythrocyte aggregation reagent;

performing a single separation step of magnetically

Assignees

• Miltenyi Biotech Gmbh
• Miltenyi Biotec Gmbh

Inventors

• Kauling Burgund
• Huppert Volker

Classifications

• G01N1/34 Primary

  Purifying; Cleaning {(processes or apparatus for extracting or separating nucleic acids from biological samples C12N15/1003)} · CPC title

• B03C1/01

  by addition of magnetic adjuvants · CPC title

• B01D21/0009

  Settling tanks making use of electricity or magnetism (electric ultra filters B01D61/425; filters making use of electricity or magnetism B01D35/06; magnetic or electrostatic separation B03C) · CPC title

• C12N5/0087 Primary

  Purging against subsets of blood cells, e.g. purging alloreactive T cells · CPC title

• B03C1/288

  disposed at the outer circumference of a recipient · CPC title